Genmab — Juni 2018
-
this is just weird and/or stupid
. New: "A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of JNJ-63723283, an Anti-Programmed Cell Death (PD)-1 Monoclonal Antibody, as Monotherapy or in Combination With Daratumumab or Erdafitinib in Japanese Participants With Advanced Solid Cancers" -
-
a the same time the ASCLEPIOS II MS trial is rectified again lol https://clinicaltrials.gov/ct2/history/NCT02792231?A=16&B=17&C=merged
-
Nivo/Dara also updated https://clinicaltrials.gov/ct2/history/NCT01592370?A=62&B=63&C=merged
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind